Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Mink Therapeutics Fiscal Q1 2022 Earnings Report | CapyFin

Mink Therapeutics

INKT · NASDAQ🇺🇸

View Company

Overview Earnings

Dividends Seasonality Metrics

Q4 2025 +3.95%Q3 2025 -1.92%Q2 2025 -13.63%Q1 2025 -3.30%Q4 2024 -3.29%Q3 2024 -5.04%Q2 2024 +0.60%Q1 2024 +6.12%Q4 2023 -2.90%Q3 2023 -11.76%Q2 2023 +1.67%Q1 2023 +13.91%Q4 2022 +0.48%Q3 2022 +14.55%Q2 2022 +13.24%Q1 2022 -26.70%Q3 2021 -6.13%Q4 2021 -6.13%Q2 2021 -42.03%Q1 2021 Q4 2020 Q3 2020 Q2 2020 Q1 2020

May 10, 2022

•

Mar 31, 2022

Mink Therapeutics Q1 2022 Earnings Report

Reported financial results for the first quarter 2022 and provided a corporate business update.

Key Takeaways

MiNK Therapeutics reported a net loss of $7.8 million for Q1 2022, which includes non-cash expenses of $813,000. The company's cash balance at the end of the quarter was $34.7 million.

Advanced ongoing clinical programs, manufacturing platform, and differentiated pipeline.

On track for data readouts this year designed to underscore the characteristics of iNKT cells.

Potential to expand durability of clinical benefit with favorable tolerability.

MiNK Internal Manufacturing Capabilities Ready for GMP Launch.

EPS

-$0.23

Previous year: -$0.135

+69.8%

Cash used in operations

$4.2M

Cash and Equivalents

$34.7M